Last reviewed · How we verify

Neither Pregabalin nor Gabapentin — Competitive Intelligence Brief

Neither Pregabalin nor Gabapentin (Neither Pregabalin nor Gabapentin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant. Area: Pain.

marketed Anticonvulsant Voltage-gated calcium channels Pain Small molecule Live · refreshed every 30 min

Target snapshot

Neither Pregabalin nor Gabapentin (Neither Pregabalin nor Gabapentin) — CAMC Health System. It works by binding to voltage-gated calcium channels in the nervous system, reducing the release of pain-causing chemicals.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Neither Pregabalin nor Gabapentin TARGET Neither Pregabalin nor Gabapentin CAMC Health System marketed Anticonvulsant Voltage-gated calcium channels
Ramipril + Felodipine Ramipril + Felodipine Sanofi marketed ACE inhibitor + calcium channel blocker combination Angiotensin-converting enzyme (ACE) and L-type voltage-gated calcium channels
Amlodipine/Atorvastatin Amlodipine/Atorvastatin Pfizer's Upjohn has merged with Mylan to form Viatris Inc. marketed Calcium channel blocker / HMG-CoA reductase inhibitor (statin) combination L-type voltage-gated calcium channels / HMG-CoA reductase
Losartan/amlodipine or losartan/hydrochlorothiazide Losartan/amlodipine or losartan/hydrochlorothiazide Yokohama City University Medical Center marketed Angiotensin II receptor blocker combination (ARB + calcium channel blocker or ARB + thiazide diuretic) Angiotensin II type 1 receptor (AT1R); L-type voltage-gated calcium channels (amlodipine) or sodium-chloride cotransporter (hydrochlorothiazide)
Magnesium Sulfate, Heptahydrate Magnesium Sulfate, Heptahydrate University of Utah marketed Electrolyte supplement / anticonvulsant / bronchodilator NMDA receptor, voltage-gated calcium channels
Telmisartan + Amlodipine Telmisartan + Amlodipine Daewon Pharmaceutical Co., Ltd. marketed Angiotensin II receptor blocker + Calcium channel blocker combination AT1 receptor (angiotensin II type 1 receptor) and L-type voltage-gated calcium channels
olmesartan medoxomil / amlodipine or azelnidipine olmesartan medoxomil / amlodipine or azelnidipine COLM Study Research Organization marketed Angiotensin II receptor blocker / Calcium channel blocker combination Angiotensin II type 1 receptor (AT1R); L-type voltage-gated calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant class)

  1. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2 drugs in this class
  2. Ajou University School of Medicine · 1 drug in this class
  3. CAMC Health System · 1 drug in this class
  4. GlaxoSmithKline · 1 drug in this class
  5. Hospital Universitari de Bellvitge · 1 drug in this class
  6. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Neither Pregabalin nor Gabapentin — Competitive Intelligence Brief. https://druglandscape.com/ci/neither-pregabalin-nor-gabapentin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: